Why CDNA rose 21.6% on Oct 30 2026: earnings guidance raise
CDNA+21.6%on Fri Oct 30 2026
CareDx, Inc. was up 21.6% on the day at $86.94, ranked #8 on 10.0× its usual five-minute volume, when TapeRank recorded this spike at 09:41 ET during regular hours.
THE DAY ON THE LIST · 1 EVENT
- 09:41 ETMOVER · REGULAR
$86.94 · ▲ 21.6% ON THE DAY · 10.0× 5M RVOL · RANK #8
JUSTIFIEDCONFIDENCE5/5CareDx is up 25.4% after reporting a major Q3 earnings and revenue beat and sharply raising FY2026 revenue and adjusted EBITDA guidance. The quantified outlook upgrade and profitability surprise provide a concrete fundamental catalyst for the move.
WHYA 25.4% gain is substantial, but it is proportionate to a 180% EPS beat, a revenue beat, and a roughly 6% to 8% FY2026 revenue-guidance increase.ANALYZED 10:00 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:41 ET
LAST86.94DAY▲ 21.6%5 MIN▼ 3.50%5M RVOL10.0×5M $VOL$10.7MFLOAT*51.7MRANK#8SESSIONREGULARVWAP85.89HOD90.87LOD76.00OR HIGH88.78OR LOW80.44PREV CLOSE71.52PM HIGH82.88PM LOW76.00GAP▲ 12.72%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $80.61, +12.7% on the previous close of $71.52
- 09:30 ETRegular-session low, $80.44
- 09:36 ETRegular-session high, $90.87
- 15:59 ETLast trade of the regular session, $87.29, +22.1% on the previous close of $71.52
- Volume: 3.3M shares in regular hours, 29K before the open
CDNA opened at $80.61 after closing at $71.52, briefly dipping to $80.44 before climbing to $90.87 by 09:36 ET. TapeRank tied the move to CareDx’s major third-quarter earnings and revenue beats and sharply raised FY2026 revenue and adjusted EBITDA guidance, including revenue guidance of $520 million to $530 million from $490 million to $500 million; TapeRank rated that explanation justified with 5/5 confidence. The stock later eased to finish the regular session at $87.29, up 22.1% from the previous close, with no halts.
WRITTEN FRI OCT 30 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 06:26 ETBTIG Maintains Buy on CareDx, Raises Price Target to $92Benzinga
- THU 16:45 ETCareDx Raises FY26 Rev Guidance To $520M-$530M Prior $490M-$500M; Raises Adj. EBITDA Guidance To $90M-$100M Prior $66M-$78MBenzinga
- THU 16:24 ETCareDx Raises FY2026 Sales Guidance from $490.000M-$500.000M to $520.000M-$530.000M vs $489.692M EstBenzinga
- THU 16:04 ET10-Q — Quarterly reportSEC 10-Q
- THU 16:02 ET8-K — Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and ExhibitsSEC 8-K
- THU 16:02 ETCareDx Q3 Adj. EPS $0.70 Beats $0.25 Estimate, Sales $139.362M Beat $120.608M EstimateBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list